Central Drug Research Institute investigators have synthesized novel compounds conjugating the quinoline moiety with a piperazine/pyrrolidine scaffold through a molecular hybridization approach and investigated their antileishmanial activity.

Researchers from Weifang Medical University and affiliated organizations have published details on the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs).

Researchers from Ipsen Ltd. and affiliated organizations presented the discovery and preclinical characterization of a novel NTCP inhibitor, A-7387, being developed for the treatment of HBV and HDV infections.

Hookipa Pharma Inc. has received clearance from the FDA for its IND application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV.

The bacterium Clostridioides difficile (C. difficile) forms organelles that help them defend against iron in the colon. According to a group of scientists from Vanderbilt University, this pathogen, which causes serious gastrointestinal infections, expresses fez genes to build structures called ferrosomes that store excess iron that is toxic to it. Its ferrosomes are surrounded by membrane and could be a target against this microorganism.

Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections. In cancer, the specificity of T-Therapeutics’ molecules will overcome shortcomings of immuno-oncology drugs such as checkpoint inhibitors that stimulate a response to some cancer neo-antigens but are unable to recognize cancer-specific self-antigens.

Researchers from Aligos Therapeutics Inc. presented preclinical data for ALG-001075, a novel capsid assembly modulator leading to the formation of empty capsids (CAM-E), being developed for the treatment of hepatitis B.